Fulgent Genetics, Inc. reiterated earnings guidance for the year 2024. For the full year 2024, Fulgent continues to expect Core Revenue of approximately $280 million and GAAP loss of approximately $2.25 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.65 USD | -3.28% | -3.46% | -28.57% |
May. 03 | Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024 | |
May. 03 | Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.57% | 618M | |
-24.16% | 7.76B | |
+68.65% | 4.33B | |
-2.98% | 2.64B | |
+2.72% | 2.63B | |
-46.17% | 2.16B | |
-22.12% | 1.46B | |
+13.62% | 1.17B | |
-43.81% | 1.14B | |
+20.41% | 999M |
- Stock Market
- Equities
- FLGT Stock
- News Fulgent Genetics, Inc.
- Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024